Discovering novel biomarkers of Central Nervous System (CNS) Disorders and Neurodegenerative Diseases is a fundamental step towards developing new personalized diagnostic, prognostic and therapeutic tools for many life-threatening CNS conditions. As of now, modern medicine still lacks accurate personalized diagnostic and therapeutic tools, which will have great impact on future clinical trials research, and which remains an urgent need for clinical management of patients with CNS conditions. Here, we highlight recent studies we conducted on Autism Spectrum Disorder (ASD), Alzheimer"s Disease, post-Severe COVID-19 sequelae with neurological complications, and ongoing work on Multiple Sclerosis Disorder, using powerful multiplex proteomics technologies such as OLINK and SENGENICS to discover novel biomarker proteins and autoantibodies of CNS conditions in patients of Qatari population, to be used for future development of diagnostic and therapeutic purposes.